# Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors

> **NCT00855452** · PHASE2 · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Malignant Melanoma
- Renal Cell Cancer
- Gastrointestinal Cancer

## Interventions

- **PROCEDURE:** one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically

## Key facts

- **NCT ID:** NCT00855452
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2015-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00855452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00855452, "Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00855452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*